Aspire Biopharma Holdings, Inc. reported on October 15, 2025, that it is at risk of being delisted from Nasdaq due to failing to meet the minimum market value and bid price requirements. The company has requested a hearing to appeal this decision and is seeking compliance by presenting its plan to the Nasdaq Hearings Panel.